In those studies, a molecular approach to knockdown CDA1 in cells as well as genetic and pharmacological approaches to knockout the CDA1 gene or inhibit CDA1’s activity in vivo are effective attenuating TGFβ signaling and ameliorating kidney injury in animal models of diabetes. This evidence concerns the gene TGFB1 and diabetes mellitus.